Awaiting green light on vaccine project

“Duopharma is mapping out its growth strategy, part of which is to move into the trading and manufacture of biosimilars (used to treat complex illnesses), oncology and regenerative therapeutic products, ’’ said group managing director Leonard Ariff Abdul Shahar (pic).

THE main focus at Duopharma Biotech is to identify a vaccine that can be filled and finished at its vaccine line; it is waiting for the government to decide which company it will choose for this task.

As the vaccine is yet to be found, the group is also uncertain on the investment required, but it is monitoring the methods of treatment that may be approved and identifying potential technology partners for this.